Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
Holding AVBP?
Track your performance easily
AVBP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.35 - $30.99
Previous Close$23.59
Volume532.79K
Average Volume (3M)156.84K
Market Cap
$792.29M
Enterprise Value$493.87M
Total Cash (Recent Filing)$298.67M
Total Debt (Recent Filing)$250.00K
Price to Earnings (P/E)―
Beta-0.23
Next Earnings
Aug 14, 2024EPS Estimate
-$0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.23
Shares Outstanding33,585,893
10 Day Avg. Volume388,116
30 Day Avg. Volume156,839
Standard Deviation0.15
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.67
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-22.58
Forecast
1Y Price Target
$36.80Price Target Upside52.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
ArriVent BioPharma, Inc. News
Bulls Say, Bears Say
Bulls Say
Clinical Trials And EfficacyFirmonertinib's chemo-free once-a-day oral option is seen as a highly desirable feature, potentially capturing a broad market and differentiating it from other treatments.
Financial PerformanceArriVent's narrower-than-expected net loss of $0.70 per share, compared to the forecasted $1.25 per share, indicates strong financial management and operational efficiency.
Strategic CollaborationsArriVent's collaboration with Jiangsu Alphamab Biopharmaceuticals to develop and commercialize novel antibody-drug conjugates (ADCs) for cancer treatment could significantly boost its product pipeline and market reach.
Bears Say
Clinical TrialsSlower than anticipated enrollment in the Phase 3 FURVENT trial.
EarningsQ1 '24 diluted GAAP EPS was ($0.70) vs JEF estimate of ($0.42) and consensus of ($1.08).
Investment RisksPossible long-term dilution risk is a concern for investors.
---
Ownership Overview
27.42% Insiders
8.69% Mutual Funds
55.68% Other Institutional Investors
8.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $14.35 and its highest was $30.99 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
Currently, no data Available
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is Aug 14, 2024 which is 37 days ago.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on May 08, 2024. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$1.077 by $0.377.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -$0.64.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 33,585,890 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$0.7 in its last earnings report, beating expectations of -$1.077. Following the earnings report the stock price went down -0.376%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Among the largest hedge funds holding ArriVent BioPharma, Inc.’s share is Perceptive Advisors LLC. It holds ArriVent BioPharma, Inc.’s shares valued at 8M.
---
ArriVent BioPharma, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.80 (52.07% Upside)
$36.80 (52.07% Upside)
Hedge Fund Trend
Decreased
By 176.8K Shares
Last Quarter.
Last Quarter.
Fundamentals
Return on Equity
-31.03%
Trailing 12-Months
Asset Growth
55.33%
Trailing 12-Months
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc.
---
AVBP Stock 12 Month Forecast
Average Price Target
$36.80
▲(52.07% Upside)
Technical Analysis
Best Analysts Covering AVBP
1 Year
---